Cargando…
Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents
Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, are limited. We retrospec...
Autores principales: | Talamo, Giampaolo, Dolloff, Nathan G., Sharma, Kamal, Zhu, Junjia, Malysz, Jozef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475946/ https://www.ncbi.nlm.nih.gov/pubmed/23087795 http://dx.doi.org/10.4081/rt.2012.e39 |
Ejemplares similares
-
Prozone effect of serum IgE levels in a case of plasma cell leukemia
por: Talamo, Giampaolo, et al.
Publicado: (2010) -
Estimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples
por: Talamo, Giampaolo, et al.
Publicado: (2015) -
Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015) -
Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents
por: Chaulagain, Chakra P, et al.
Publicado: (2021) -
Dermatopathology of Malignant Melanoma in the Era of Artificial Intelligence: A Single Institutional Experience
por: Cazzato, Gerardo, et al.
Publicado: (2022)